Next Article in Journal
Expression of PD-L1 for Predicting Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis
Previous Article in Journal
First-Line Therapy, Autologous Stem-Cell Transplantation, and Post-Transplantation Maintenance in the Management of Newly Diagnosed Mantle Cell Lymphoma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 27
Issue 6
10.3747/co.27.6795
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Bruton Tyrosine Kinase Inhibitors for the Frontline Treatment of Chronic Lymphocytic Leukemia

by
Versha Banerji
1,*,
A. Aw
2,
S. Robinson
3,
S. Doucette
4,
A. Christofides
4 and
L.H. Sehn
5
1
Departments of Internal Medicine and Biochemistry and Medical Genetics, Max Rady College of Medicine, Rady Faculty of Health Science, University of Manitoba and Research Institute of Oncology and Hematology at CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada
2
Ottawa Blood Disease Centre, University of Ottawa, Ottawa, ON, Canada
3
Division of Hematology, Dalhousie University, Halifax, NS, Canada
4
Impact Medicom Inc., Toronto, ON, Canada
5
BC Cancer–Centre for Lymphoid Cancer, and University of British Columbia, Vancouver, BC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2020, 27(6), 645-655; https://doi.org/10.3747/co.27.6795
Submission received: 2 September 2020 / Revised: 4 October 2020 / Accepted: 6 November 2020 / Published: 1 December 2020

Abstract

Chronic lymphocytic leukemia (cll) is the most commonly diagnosed adult leukemia in Canada. Biologic heterogeneity of cll between patients results in variable disease trajectories and responses to therapy. Notably, compared with patients lacking high-risk features, those with such features—such as deletions in chromosome 17p, aberrations in the TP53 gene, or unmutated immunoglobulin heavy chain variable region genes—experience inferior outcomes and responses to standard chemoimmunotherapy. Novel agents that target the B cell receptor signalling pathway, such as Bruton tyrosine kinase (btk) inhibitors, have demonstrated clinical efficacy and safety in patients with treatment-naïve cll, particularly those with high-risk features. However, given the current lack of head-to-head trials comparing btk inhibitors, selection of the optimal btk inhibitor for patients with cll is unclear and requires consideration of multiple factors. In the present review, we focus on the efficacy, safety, and pharmacologic features of the btk inhibitors that are approved or under clinical development, and we discuss the practical considerations for the use of those agents in the Canadian treatment landscape.
Keywords: bruton tyrosine kinase inhibitors; chronic lymphocytic leukemia; untreated disease; frontline therapy; first-line therapy bruton tyrosine kinase inhibitors; chronic lymphocytic leukemia; untreated disease; frontline therapy; first-line therapy

Share and Cite

MDPI and ACS Style

Banerji, V.; Aw, A.; Robinson, S.; Doucette, S.; Christofides, A.; Sehn, L.H. Bruton Tyrosine Kinase Inhibitors for the Frontline Treatment of Chronic Lymphocytic Leukemia. Curr. Oncol. 2020, 27, 645-655. https://doi.org/10.3747/co.27.6795

AMA Style

Banerji V, Aw A, Robinson S, Doucette S, Christofides A, Sehn LH. Bruton Tyrosine Kinase Inhibitors for the Frontline Treatment of Chronic Lymphocytic Leukemia. Current Oncology. 2020; 27(6):645-655. https://doi.org/10.3747/co.27.6795

Chicago/Turabian Style

Banerji, Versha, A. Aw, S. Robinson, S. Doucette, A. Christofides, and L.H. Sehn. 2020. "Bruton Tyrosine Kinase Inhibitors for the Frontline Treatment of Chronic Lymphocytic Leukemia" Current Oncology 27, no. 6: 645-655. https://doi.org/10.3747/co.27.6795

APA Style

Banerji, V., Aw, A., Robinson, S., Doucette, S., Christofides, A., & Sehn, L. H. (2020). Bruton Tyrosine Kinase Inhibitors for the Frontline Treatment of Chronic Lymphocytic Leukemia. Current Oncology, 27(6), 645-655. https://doi.org/10.3747/co.27.6795

Article Metrics

Back to TopTop